ORI
CORT icon

Oak Ridge Investments’s Corcept Therapeutics CORT Stock Holding History

Oak Ridge Investments’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97M Buy
34,172
+9,302
+37% +$562K 0.17% 83
2026
Q1 		$1M Buy
24,870
+257
+1% +$9.61K 0.07% 125
2025
Q4 		$857K Sell
24,613
-887
-3% -$69.7K 0.05% 131
2025
Q3 		$2.12M Buy
25,500
+2,177
+9% +$158K 0.14% 89
2025
Q2 		$1.71M Buy
23,323
+2,784
+14% +$202K 0.12% 96
2025
Q1 		$2.35M Sell
20,539
-8,452
-29% -$514K 0.2% 78
2024
Q4 		$1.46M Sell
28,991
-89
-0.3% -$4.66K 0.11% 103
2024
Q3 		$1.35M Sell
29,080
-1,192
-4% -$42.4K 0.12% 99
2024
Q2 		$984K Buy
+30,272
New +$829K 0.09% 112
2019
Q1 		– Sell
-381,567
Closed -$5.1M – 170
2018
Q4 		$5.1M Sell
381,567
-142,243
-27% -$1.88M 0.37% 97
2018
Q3 		$7.34M Sell
523,810
-65,570
-11% -$916K 0.41% 92
2018
Q2 		$9.27M Buy
589,380
+148,212
+34% +$2.58M 0.53% 85
2018
Q1 		$7.26M Sell
441,168
-119,886
-21% -$2.22M 0.4% 89
2017
Q4 		$10.1M Buy
+561,054
New +$10.2M 0.48% 80

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oak Ridge Investments's CORT Position: Q2 2026 in Review

Oak Ridge Investments increased its Corcept Therapeutics (CORT) stake by 37% in Q2 2026, buying an estimated $562K and bringing the position to 34,172 shares worth $2.97M. The position accounts for 0.17% of the portfolio, ranked #83.

Oak Ridge Investments first reported a position in CORT in Q4 2017 and has held it in 14 quarters since. The position peaked at $10.1M in Q4 2017. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Oak Ridge Investments held 34,172 shares of Corcept Therapeutics worth $2.97M as of Q2 2026.
  • Oak Ridge Investments bought 9,302 Corcept Therapeutics shares in Q2 2026, an estimated $562K.
  • Corcept Therapeutics made up 0.17% of Oak Ridge Investments's portfolio in Q2 2026, its #83 holding.
  • Oak Ridge Investments first reported a position in Corcept Therapeutics in Q4 2017 and has held it in 14 quarters since.
  • Oak Ridge Investments's Corcept Therapeutics position peaked at $10.1M in Q4 2017.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Oak Ridge Investments's 13F filing for Q2 2026, filed 21 Jul 2026.